Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib with weekly paclitaxel and carboplatin in platinum-resistant or platinum-refractory ovarian, fallopian tube, or primary peritoneal carcinoma
NL-OMON39032Phase 2Active, not recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Oct 2012
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pazopanib, paclitaxel and carboplatin in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoints: Dose-limiting toxicity and Maximum tolerated dose. Started Oct 2012; status: active, not recruiting.
02
Drugs
pazopanibpaclitaxelcarboplatin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NL-OMON39032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39032.